Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…
A protein known as MCJ might be a target of treatments needed to preserve heart function in people with pulmonary hypertension (PH), a study reports. Elevated levels of MCJ were found in the lung tissue of individuals affected by the low oxygen conditions of chronic obstructive pulmonary disease…
After a diagnosis of pulmonary arterial hypertension (PAH), rapidly starting treatment with a combination of therapies — both an endothelin receptor antagonist (ERA) and a phosphodiesterase type 5 inhibitor (PDE5i) — can lead to notable short-term improvements in heart health and physical function. That’s according to a new…
In people with pulmonary hypertension (PH), the endothelial cells that line the inside of blood vessels in the lungs take on features that are similar to what’s seen in some cancers, a new study found. The researchers who uncovered these features in these hard-to-access cells noted that they may…
Sensydia announced that it successfully completed a fifth study of its investigative Cardiac Performance System (CPS), intended to more easily and quickly detect pulmonary hypertension (PH) and heart failure than current approaches. CPS is a handheld and noninvasive device, powered by artificial intelligence, that uses heart sound…
Two genes were identified as potential drivers of pulmonary arterial hypertension (PAH) in a bioinformatics study, offering opportunities to better understand the disease and explore their use as biomarkers or therapeutic targets. The genes, called WDR43 and GNL2, were more active in the lungs of people with PAH than…
Four microRNAs (miRNAs) — small RNA molecules that regulate protein production — were found at different levels in blood samples from people with pulmonary hypertension (PH) compared with healthy people, a small study reported. Levels of two of these miRNAs were significantly higher in the PH patients versus the…
The first participant has entered ASCENT, a clinical study into the safety and tolerability of Liquidia’s Yutrepia, an inhaled dry powder formulation of treprostinil that is under regulatory review for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The open-label study (NCT06129240) seeks to enroll an estimated…
People with pulmonary arterial hypertension (PAH) related to use of methamphetamine — a potent stimulant only legally available by prescription — tend to have worse heart health and poorer exercise capacity compared with patients with other forms of PAH. That’s according to a new study, “Methamphetamine-associated…
Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as heart function and blood flow parameters, varied widely…
Atrial fibrillation or AF — a heart condition marked by an irregular heartbeat — is associated with longer hospital stays, higher inpatient mortality, and greater hospitalization costs in patients with pulmonary hypertension (PH), according to a new large-scale study. The findings indicate that this heart condition, common in people…
While about a quarter of pulmonary arterial hypertension (PAH) patients treated with the investigational therapy sotatercept tested positive for antibodies against it, the antibodies didn’t influence the therapy’s safety or effectiveness, according to a clinical trial analysis. The study, “The impact of immunogenicity on the pharmacokinetics,…
Get regular updates to your inbox.